Literature DB >> 12827055

Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia.

Ji Jin1, Ming Guan, Jing Sima, Guoquan Gao, Mei Zhang, Zhuguo Liu, James Fant, Jian-xing Ma.   

Abstract

PURPOSE: Pterygia are histologically composed of proliferating fibrovascular tissue. This study compared expression levels of an angiogenic inhibitor, pigment epithelium-derived factor (PEDF), in pterygia with those in normal corneal and conjunctival tissues.
METHODS: The normal human conjunctival and corneal tissues were obtained from surgery or from donor eyes without ocular diseases. Pterygia were excised by therapeutic surgery under a microscope. Pigment epithelium-derived factor and vascular endothelial growth factor (VEGF) were measured by Western blot analysis. Their cellular localizations were determined by immunohistochemistry.
RESULTS: Intensive PEDF immunostaining was detected in all the normal corneal and conjunctival samples analyzed, predominantly in the epithelium and endothelium of the cornea and in the epithelium of the limbus and conjunctiva. Under the same immunostaining conditions, pterygial samples showed negative or faint PEDF staining. In contrast, the same pterygial samples all showed intensive VEGF staining, predominantly in the epithelium and in blood vessels. Western blot analysis confirmed that the average PEDF level in pterygia was drastically lower than those in normal corneal and conjunctival tissues, respectively. In contrast, the VEGF level in pterygia was significantly higher than in the normal tissues.
CONCLUSION: Pterygia exhibit significantly lower PEDF but higher VEGF levels than those in normal corneas and conjunctivae. The decreased PEDF level in pterygia may play a role in the formation and progression of pterygia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12827055     DOI: 10.1097/00003226-200307000-00015

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  22 in total

1.  Subconjunctival bevacizumab in the impending recurrent pterygia.

Authors:  Sezin Akca Bayar; Cem Kucukerdonmez; Ozlem Oner; Yonca A Akova
Journal:  Int Ophthalmol       Date:  2013-09-12       Impact factor: 2.031

2.  Inhibitory effect of PPARγ agonist on the proliferation of human pterygium fibroblasts.

Authors:  Yuan Zou; Mingchang Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-12-22

3.  Bevacizumab as adjuvant therapy in the management of pterygium: a systematic review and Meta-analysis.

Authors:  Jian Liu; Jie-Hui Xu; Wen Xu; Guan-Lu Liang; Ji-Xian Lou; Yi Wang; Ji-Quan Wen; Yong-Bao Cao
Journal:  Int J Ophthalmol       Date:  2017-07-18       Impact factor: 1.779

4.  The Key Role of VEGF in the Cross Talk between Pterygium and Dry Eye and Its Clinical Significance.

Authors:  Chang Liu; Yiyue Song; Xiaoran Wang; Zhaoguang Lai; Chaoyang Li; Pengxia Wan; Nuo Xu; Danping Huang; Yizhi Liu; Zhichong Wang
Journal:  Ophthalmic Res       Date:  2020-01-10       Impact factor: 2.892

Review 5.  Myofibroblast transdifferentiation: The dark force in ocular wound healing and fibrosis.

Authors:  Daisy Y Shu; Frank J Lovicu
Journal:  Prog Retin Eye Res       Date:  2017-08-12       Impact factor: 21.198

6.  Does topical bevacizumab prevent postoperative recurrence after pterygium surgery with conjunctival autografting?

Authors:  Aylin Karalezli; Cem Kucukerdonmez; Yonca A Akova; Bengu Ekinci Koktekir
Journal:  Int J Ophthalmol       Date:  2014-06-18       Impact factor: 1.779

7.  Efficacy and Safety of a Large Conjunctival Autograft for Recurrent Pterygium.

Authors:  Jun Seok Lee; Sang Won Ha; Sung Yu; Gwang Ja Lee; Young Jeung Park
Journal:  Korean J Ophthalmol       Date:  2017-12

8.  Correlation of vascular endothelial growth factor and CD105-microvascular density in primary pterygium.

Authors:  Jie Zhang; Mingchang Zhang; Xiaoqing Li; Tian Zheng; Ge Mu; Wei Liu; Huatao Xie; Xin Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-08-07

9.  Effect of single subconjunctival injection of bevacizumab on primary pterygium: clinical, histopathological and immunohistochemical study.

Authors:  Tarek A Mohamed; Wael Soliman; Ahmed M Fathalla; Abeer El Refaie
Journal:  Int J Ophthalmol       Date:  2018-05-18       Impact factor: 1.779

Review 10.  Novel aspects of corneal angiogenic and lymphangiogenic privilege.

Authors:  David Ellenberg; Dimitri T Azar; Joelle A Hallak; Faisal Tobaigy; Kyu Yeon Han; Sandeep Jain; Zhongjun Zhou; Jin-Hong Chang
Journal:  Prog Retin Eye Res       Date:  2010-01-25       Impact factor: 21.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.